Sign in
Taking people in United StatesNo phase

Screening people with smoldering multiple myeloma for early amyloidosis

Checks for early light-chain amyloidosis in adults 40 or older with smoldering myeloma.

Key facts

Who runs it
Tufts Medical Center
Where
Birmingham, Boston, Charlotte, Columbus, Dallas, Durham, Los Angeles, New York, Richmond, Salt Lake City, San Francisco, and Weston, United StatesSee the 13 sites
Trial code
Registry title
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Status
Recruiting
People taking part
400 people, planned
Started
1 May 2024
Expected to end
27 Feb 2029
Type of study
Observational
Record updated
26 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 or older with smoldering multiple myeloma or a monoclonal gammopathy. It checks for light-chain (AL) amyloidosis before symptoms start.

Age
40 years and older
Sex
All sexes can join.
Disease stage
Smoldering multiple myeloma or a monoclonal gammopathy.
Biomarker or test result
dFLC greater than 23 mg/L and an abnormal FLC ratio. If eGFR is less than 50 mL/min/1.73m2, only age and dFLC count.

Main reasons for not taking part

  • Younger than 40 years
  • Amyloid found in an earlier biopsy
  • Adults unable to consent, including the cognitively impaired
  • Pregnant women and minors
  • Wards of the state and prisoners

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patients 40 years of age and older
  • diagnosed with either Smoldering Multiple Myeloma or a Monoclonal Gammopathy
  • dFLC greater than 23 mg/L
  • abnormal FLC ratio
  • If the patient has an eGFR less than 50 mL/min/1.73m2, the FLC ratio is inconsequential. The patient only needs to meet the age and dFLC criterion

Who cannot take part

  • Patients with a previous finding of amyloid in other biopsies will not be included
  • Patients younger than 40 years of age are not eligible
  • Adults unable to consent are not eligible, including the cognitively impaired Pregnant women, pregnant minors, minors (i.e., individuals who are not yet adults), wards of the state, non-viable neonates, neonates of uncertain viability, and prisoners are not eligible

Where in United States

  • University of Alabama HospitalBirmingham, United StatesContact: Megan MaierTaking people
  • Tufts Medical CenterBoston, United StatesContact: Denis ToskicTaking people
  • Atrium Health Levine Cancer InstituteCharlotte, United StatesContact: Courtney SchepelTaking people
  • The Ohio State University Comprehensive Cancer CenterColumbus, United StatesContact: Naresh Bumma, MD (principal investigator)Taking people
  • UT Southwestern, Harold C. Simmons Comprehensive Cancer CenterDallas, United StatesContact: Larry Anderson, MD (principal investigator)Not yet recruiting
  • UNC Lineberger Comprehensive Cancer CenterDurham, United StatesContact: Kendall ConderTaking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Robert Vescio, MD (principal investigator)Taking people
  • Columbia University Irving Medical CenterNew York, United StatesContact: CUIMC NavigatorsTaking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Khayla LeivaTaking people
  • VCU Medical CenterRichmond, United StatesContact: Zackary MooreTaking people
  • University of Utah, Huntsman Cancer HospitalSalt Lake City, United StatesContact: Sharmilee NuliTaking people
  • University of California San FranciscoSan Francisco, United StatesContact: Ruixin SunTaking people
  • Cleveland Clinic Florida, Weston HospitalWeston, United StatesContact: Chakra Chaulagain, MD (principal investigator)Taking people

About the trial

What the trial wants to find out

In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Plain-language title
Screening people with smoldering multiple myeloma for early amyloidosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 October 2026